enGene (NASDAQ:ENGN) Announces Quarterly Earnings Results, Misses Estimates By $0.04 EPS

enGene (NASDAQ:ENGN) released its quarterly earnings data on Tuesday. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.04), FiscalAI reports.

Here are the key takeaways from enGene’s conference call:

• enGene reported $266 million in cash, which management says should fund operations through the planned late-2026 BLA filing and anticipated approval in 2027.
• Interim LEGEND data showed a 54% complete response rate at any time and approximately 25% projected 12-month complete response, with very low treatment interruption or discontinuation of 2.4%; however, durability data remain immature and the statistical analysis plan is not yet finalized.
• Management believes detalimogene is particularly well positioned for community urologists because it can be stored and administered relatively easily, requires no special viral-handling infrastructure, and has a favorable tolerability profile.
• The company remains on track for a fourth-quarter pre-BLA meeting and emphasized that its manufacturing validation runs are complete, potentially reducing regulatory risk in an area where recent oncology approvals have faced manufacturing-related setbacks.
• A surfactant combination cohort completed its safety run-in without dose-limiting toxicities; management expects the approach could improve drug expression, efficacy, durability, and treatment convenience, though clinical benefits remain unproven.

enGene Stock Up 5.5%

enGene stock opened at $1.92 on Wednesday. enGene has a fifty-two week low of $1.40 and a fifty-two week high of $12.25. The company’s 50-day moving average is $1.82 and its 200-day moving average is $4.05. The company has a debt-to-equity ratio of 0.10, a current ratio of 12.57 and a quick ratio of 12.57. The firm has a market capitalization of $128.62 million, a PE ratio of -0.88 and a beta of -0.28.

Trending Headlines about enGene

Here are the key news stories impacting enGene this week:

• Positive Sentiment: Analyst reaffirmation: HC Wainwright reaffirmed its “buy” rating and maintained a $4.00 price target, implying substantial upside from the stock’s recent $1.92 level. The endorsement may improve investor sentiment toward the clinical-stage biotechnology company.
• Positive Sentiment: Regulatory and clinical progress: enGene said it is focused on maturing regulatory-endpoint data from the pivotal LEGEND cohort and plans to engage with the FDA regarding a potential biologics license application for detalimogene. Progress toward a BLA could provide an important future catalyst. enGene Reports Third Quarter 2026 Financial Results and Provides Business Update
• Neutral Sentiment: Quarterly results met expectations: enGene reported a third-quarter loss of $0.47 per share, matching the analyst consensus estimate. While the results avoided a negative earnings surprise, the company remains unprofitable, with analysts expecting a full-year loss.
• Negative Sentiment: Technical and development risk remain: At approximately $1.92, enGene trades substantially below its 200-day simple moving average of $4.05 and remains close to its one-year low. As a clinical-stage company, its valuation continues to depend heavily on trial data, FDA discussions and its ability to advance detalimogene toward commercialization.

Analyst Upgrades and Downgrades

Several analysts have issued reports on ENGN shares. Citigroup reissued a “market perform” rating on shares of enGene in a research note on Wednesday. Weiss Ratings reissued a “sell (e+)” rating on shares of enGene in a research report on Wednesday, August 12th. UBS Group dropped their target price on shares of enGene from $9.00 to $2.00 and set a “neutral” rating on the stock in a research report on Thursday, May 14th. Morgan Stanley lowered enGene from an “equal weight” rating to an “underweight” rating and set a $3.00 price objective on the stock. in a report on Thursday, June 18th. Finally, Wall Street Zen upgraded enGene from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 15th. Four equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $11.05.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Cresset Asset Management LLC acquired a new stake in enGene in the second quarter valued at approximately $36,000. Paloma Partners Management Co bought a new position in enGene in the second quarter worth approximately $38,000. Raymond James Financial Inc. grew its position in enGene by 383.6% in the 3rd quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock valued at $68,000 after purchasing an additional 7,932 shares during the period. Citadel Advisors LLC grew its holdings in shares of enGene by 153.3% during the third quarter. Citadel Advisors LLC now owns 58,370 shares of the company’s stock valued at $399,000 after buying an additional 35,327 shares during the last quarter. Finally, Millennium Management LLC increased its holdings in enGene by 57.3% during the 3rd quarter. Millennium Management LLC now owns 20,502 shares of the company’s stock worth $140,000 after purchasing an additional 7,472 shares in the last quarter. Institutional investors own 64.16% of the company’s stock.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.